Merck & Company (MRK) Buy, Sell or Hold

Merck & Company (MRK)

114.20

+0.33 (0.29%)

as of Jun 18, 2026, 11:15:03 pm Market Open.

161 watching

BUY

Prefers Pfizer (PFE-N) even though in the near term this company has outperformed them. If you are looking to own a pharmaceutical, this is a fine name.

DON'T BUY

Model price is $48.07, a negative 7.5% differential.

PAST TOP PICK

(A Top Pick Sept 13/06. Up 7.3%.) Pharmaceutical stocks fit in the theme of large cap capital growth. Expect this to be a good stock this year without a lot of risk.

TOP PICK

The company went through a lot of bad news over the last four months but in the last 3 quarters there has been a re-acceleration in their growth rate. Trades at a very reasonable multiple.

WEAK BUY

Likes the sector. The names have been incredibly punished in the last few years. They still look cheap. This one had additional problems with Viox, but is recovering nicely. Wouldn't be his first pick.

BUY

All the major drug stocks are starting to act better. In this type of market, money moves from risky stocks to defensive stocks. A good place to be.

BUY

Great dividend yield. Probably one of the worst performing sectors in the S&P. Lots of cost cutting opportunities. Trading at around 8/9 X earnings. Pristine balance sheet.

DON'T BUY

Prefers Pfizer which has been doing more things correctly.

HOLD

This is a sector that he has avoided as they have had three years of poor experience. In the last 3/4 months, pharmaceuticals have started to wake up. This will not be the fastest growing area and this one will plod along.

BUY

Big pharmas have had a really tough go. He can now see them coming back. A good selection for a conservative, patient investor.

DON'T BUY

Has a lot of lawsuits overhanging it. Would not own it at this point.

PAST TOP PICK

(A Top Pick Aug 29/05. Up 14%.) Loves this name. An absolute steal. Facing class action lawsuits. This is what a value manager wants. A great company with a ton of free cash flow, strong dividend, pristine balance sheet and everybody hates.

DON'T BUY

Too early, particularly if the US has a recession. If we get into a recession, it will be a consumer led recession, there’s going to be humongous pressures by consumers and seniors on drugs for some of the egregious profits they have been making.

DON'T BUY

Drug stars such as Pfizer (PFE-N) Merck (MRK-N), etc. are attractively valued but are clearly out of favour. They have great long term track records and are in strong financial positions, however, there is a lack of predictability regarding the science. Doesn't like the cash flow dynamics where they spend billions up front with no sure win ahead. Litigation risks.

BUY

Pays a 5.5% dividend. If you have good fundamentals plus a dividend yield, you should do OK.

Showing 166 to 180 of 252 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

Stockchase Insights

5i Research

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Merck & Company (MRK)